AsianScientist (Mar. 9, 2018) – Takeda Pharmaceuticals has announced the establishment of a Center of Excellence (CoE) in Singapore for vaccine process optimization. This CoE, supported by the Singapore Economic Development Board (EDB), facilitates the immediate hire and training of additional Singapore talent who will work on Takeda’s current and future vaccine candidates. These vaccine candidates will help address diseases such as dengue, Zika and polio, which present some of the world’s most challenging health problems.
“The partnership with the EDB will help us take advantage of the growing talent pool and innovation hub for which Singapore has become well known,” said Dr. Rahul Singhvi, Chief Operating Officer at Takeda. “This is an important milestone in our efforts to support and expand vaccine development as we work to bring them to people worldwide.”
With the support of the EDB, Takeda will hire scientists who are Singaporean Citizens or Permanent Residents of Singapore. Takeda will be responsible for the training and upskilling of successful candidates to enhance process and manufacturing development skills by leveraging Takeda’s world class manufacturing facility in Hikari, Japan.
“We are pleased that Takeda is expanding and deepening their presence in Singapore. Process development and optimization remains a key part of vaccine development, and this CoE demonstrates Singapore’s capabilities in supporting pharmaceutical companies to bring innovative products to market. It is also testament to Singapore’s attractiveness as a location for world-class R&D activities and talent,” said Ms. Ho Weng Si, Director, Biomedical Sciences, EDB.
———
Source: Takeda; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
